摘要
目的：观察溶栓后早期PCI治疗急性ST段抬高型心肌梗死（STEMI）术中应用替罗非班的临床疗效及安全性.方法：按照实际救治情况将106例STEMI患者分为溶栓后早期PCI使用替罗非班组（A组,52）和单独溶栓后早期PCI组（B组,54例）,随访30 d,对比两组梗死相关血管TIMI血流及TIMI心肌灌注（TMP）2~3级情况、左心室功能及复合终点和出血情况.结果：两组基线无差异,术前TIMI 3级和TMP 2~3级水平间差异无统计学意义（P＞0.05）,介入完成后两组TIMI血流3级率无显著性差异,但A组TMP 2~3级率显著高于B组（96.4% VS 75.5%,P＜0.05）.30 d随访两组左室射血分数、复合终点事件及出血差异无统计学意义（P＞0.05）.结论：溶栓后早期PCI联合替罗非班治疗安全有效,不增加出血并发症,值得进一步临床探索.
Objective To observe the treatment effect and safety of the STEMI patients with Post -fibrinolysis Angioplasty combined Tirofiban. Method 106 STEMI patients were divided into 2 groups according to clinical therapy. One group accepted Post - fibrinolysis An- gioplasty combined Tirofiban （ A group,n = 52） ,the other group only Post - fibfinolysis Angioplasty （ B group, n = 54）. Compared the TIMI flow,TIMI myocardial perfusion,left ventricular function and bleeding event ,the compound endpoints between two groups in perfusing the infarction related artery （IRA） after 30 days followup. Results The baselines of two group were similar,after PCI the TIMI 3 grade wassimilar in 2 groups （ P 〉 0. 05 ）, but TMP 2 - 3 grade was higher in A group than B group （96. 4% VS 75.5 %, P 〈 0. 05 ）, follow - up data were similar in left ventricular function and bleeding event ~the compound endpoints between two groups. Conclusion Post - fibrinolysis Angioplasty combined Tirofiban is a safety,efflcacy treatment method and this therapeutic methods will be worthy of deeply searching for treating AMI in clinc.
出处
《吉林医学》
CAS
2013年第28期5800-5803,共4页
Jilin Medical Journal
关键词
心肌梗死
介入治疗
溶栓
替罗非班
微循环
Myocardial infarction
Percutaneous coronary intervention
Fibrinolysis
Tirofiban
Micro - circulation
